Literature DB >> 23152299

Neoadjuvant chemotherapy evaluation by MRI volumetry in rectal cancer followed by chemoradiation and total mesorectal excision: Initial experience.

Stephanie Nougaret1, Shinya Fujii, Helen C Addley, Frederic Bibeau, Himanshu Pandey, Hisham Mikhael, Caroline Reinhold, David Azria, Philippe Rouanet, Benoit Gallix.   

Abstract

PURPOSE: To evaluate rectal cancer volumetry in predicting initial neoadjuvant chemotherapy response.
MATERIALS AND METHODS: Sixteen consecutive patients who underwent neoadjuvant chemotherapy (CX) before chemoradiotherapy (CRT) and surgery were enrolled in this retrospective study. Tumor volume was evaluated at the first magnetic resonance imaging (MRI), after CX and after CRT. Tumor volume regression (TVR) and downstaging were compared with histological results according to Tumor Regression Grade (TRG) to assess CX and CRT response, respectively.
RESULTS: The mean tumor volume was 132 cm(3) ± 166 before and 56 cm(3) ± 71 after CX. TVR after CX was significantly different between patients with poor histologic response (TRG1/2) and those with good histologic response (TRG3/4) (P = 0.001). An optimal cutoff of TVR >68% (area under the curve [AUC]: 0.9, 95% confidence interval [CI]: 0.65-0.98, P = 0.0001) to predict good histology response after CX was assessed by receiver operating characteristic curve. According to previous data and this study, we defined 70% as the best cutoff values according to sensitivity (86%), specificity (100%) of TVR for predicting good histology response. In contradistinction, MRI downstaging was associated with TRG only after CRT (P = 0.04).
CONCLUSION: Our pilot study showed that MRI volumetry can predict early histological response after CX and before CRT. MRI volumetry could help the clinician to distinguish early responders in order to aid appropriate individually tailored therapies.
Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Keywords:  MRI volumetry; chemotherapy; rectal cancer

Mesh:

Year:  2012        PMID: 23152299     DOI: 10.1002/jmri.23905

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  9 in total

1.  MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Authors:  T Seierstad; K H Hole; K K Grøholt; S Dueland; A H Ree; K Flatmark; K R Redalen
Journal:  Br J Radiol       Date:  2015-04-22       Impact factor: 3.039

2.  Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade.

Authors:  Stephanie Nougaret; Caroline Reinhold; Shaza S Alsharif; Helen Addley; Jocelyne Arceneau; Nicolas Molinari; Boris Guiu; Evis Sala
Journal:  Radiology       Date:  2015-04-30       Impact factor: 11.105

3.  (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  Junichi Nishimura; Junichi Hasegawa; Yoji Ogawa; Hideaki Miwa; Mamoru Uemura; Naotsugu Haraguchi; Taishi Hata; Hirofumi Yamamoto; Ichiro Takemasa; Tsunekazu Mizushima; Riichiro Nezu; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2015-12-28       Impact factor: 2.549

4.  Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer.

Authors:  Torbjörn Swartling; Peter Kälebo; Kristoffer Derwinger; Bengt Gustavsson; Göran Kurlberg
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

5.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

6.  Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters.

Authors:  Andreas M Hötker; Lisa Tarlinton; Yousef Mazaheri; Kaitlin M Woo; Mithat Gönen; Leonard B Saltz; Karyn A Goodman; Julio Garcia-Aguilar; Marc J Gollub
Journal:  Eur Radiol       Date:  2016-03-05       Impact factor: 5.315

7.  The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer.

Authors:  Stephan B Dreyer; Arfon G M T Powell; Stephen T McSorley; Ashita Waterston; James J Going; Joanne Edwards; Donald C McMillan; Paul G Horgan
Journal:  Ann Surg Oncol       Date:  2016-11-21       Impact factor: 5.344

8.  Prediction of Response to Neoadjuvant Chemoradiotherapy by MRI-Based Machine Learning Texture Analysis in Rectal Cancer Patients.

Authors:  Sajad P Shayesteh; Afsaneh Alikhassi; Farshid Farhan; Reza Ghalehtaki; Masume Soltanabadi; Peiman Haddad; Ahmad Bitarafan-Rajabi
Journal:  J Gastrointest Cancer       Date:  2020-06

9.  The predictive value of tumor volume reduction ratio on three-dimensional endorectal ultrasound for tumor response to chemoradiotherapy for locally advanced rectal cancer.

Authors:  Limei Chen; Xiaoyin Liu; Wenjing Zhang; Si Qin; Yimin Wang; Jing Lin; Qiu Chen; Guangjian Liu
Journal:  Ann Transl Med       Date:  2022-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.